They are talking about herbal extract ma huang which is a natural substance that does not come under FDA review unless they receive reports of harm or inappropriate claims of benefit. It took a lot of doing to get it off the OTC shelves.
<< The authors reviewed all 1,820 adverse event reports related to dietary supplements containing herbal ephedra >>
This is part of an alternative medicine culture where the buyer must beware. Clearly the FDA is overworked and underfunded.
It is easy to lay the blame on the FDA when jumping to conclusions. Aren't we short on information with COR administration as well, when we give them a failing grade.
Today the biggest BP wrote of $2.6 billion and walked away from inhaled insulin, an FDA approved drug. What would you say about PFE management? What are the odds of bringing an ampakine to profitability with the best management that money can buy?
Market Data 
Markets 
AI
